Endohepatology Assessment in Adults at High Risk of Fatty Liver Disease
Examines whether endohepatology testing changes treatment plans in adults at high risk of MASLD.
Plain-language title generated from the registry record
Registry title: Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLD
Key facts
- Where
- Münster, GermanySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults 18 or older with suspected fatty liver disease linked to metabolic problems (MASLD) who have at least one predefined risk factor. It checks whether a detailed liver assessment changes the treatment plan.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Suspected MASLD with at least one predefined risk criterion. People with decompensated cirrhosis or vascular liver disease cannot join.
- Earlier treatment
- People currently on resmetirom therapy cannot join. People with a previous organ transplant or TIPS cannot join.
Main reasons for not taking part
- No evidence of MASLD
- HIV infection
- Previous organ transplant or TIPS
- Decompensated cirrhosis
- Pregnancy or breastfeeding
Read by machine on 13 November 2026.
Where in Germany
- University hospital MuensterMünster, GermanyContact: Michael Prof. PraktiknjoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Hospital Muenster
- Trial code
- NCT07877272
- Record updated
- 20 October 2026
- Original description
This prospective observational study evaluates whether endohepatology changes treatment indications in adults at high risk of metabolic dysfunction-associated steatotic liver disease. Non-invasive testing is followed, when indicated, by a single-session endohepatology assessment including EUS-guided shear-wave elastography, portal pressure gradient measurement and liver biopsy. The primary outcome is treatment reclassification compared with the prospectively documented non-invasive assessment.Read full original descriptionShow less
Endohepatology-Based Reclassification of Treatment Indication in High-Risk Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective, Multicenter Observational Study
This prospective observational study evaluates whether endohepatology changes treatment indications in adults at high risk of metabolic dysfunction-associated steatotic liver disease. Non-invasive testing is followed, when indicated, by a single-session endohepatology assessment including EUS-guided shear-wave elastography, portal pressure gradient measurement and liver biopsy. The primary outcome is treatment reclassification compared with the prospectively documented non-invasive assessment.
Inclusion: Age 18 years or older; Written informed consent; Suspected MASLD; At least one predefined risk criterion.
Exclusion: Previous organ transplantation or TIPS; Current resmetirom therapy; HIV infection; Vascular liver disease; No evidence of MASLD; Decompensated cirrhosis; Contraindication to endoscopy, sedation, or liver biopsy; Pregnancy or breastfeeding; Inability to provide informed consent.